BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies (P9-2.010)
{{output}}
Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an investigational TYK2/JAK1 inhibitor in healthy adults. Background: ... ...
